There is a particular cruelty to what is happening to independent dermatologists right now.
You trained for years to master one of medicine's most nuanced specialties. You understand the difference between a contact dermatitis and a drug eruption at a glance. You know when a lesion needs a biopsy and when it doesn't. You have dedicated your career to caring for patients whose conditions are often dismissed as cosmetic — when the reality is that chronic skin disease can be debilitating, isolating, and life-altering.
And now a significant portion of your working week has nothing to do with any of that.
It has to do with prior authorization.
The Numbers Are Staggering
The prior authorization burden in dermatology is among the highest in all of medicine — and it is getting worse.
Think about what that 60% figure means in practice. A patient is in the exam chair. You are in the middle of a consultation. And someone knocks on the door because an insurer needs more documentation on a biologic you prescribed three weeks ago.
And that 17% is not a billing problem. That is a patient care problem. Prior authorization is changing the clinical decisions independent dermatologists make — not because a better treatment doesn't exist, but because the barrier to accessing it is simply too high.
The volume is also accelerating. Prior authorization requests at academic dermatology clinics grew at 30 times the rate of clinical volume between 2016 and 2018. There is no reason to believe that trend has reversed.
Biologics: The Epicenter of the Crisis
If prior authorization is the problem, biologics are where it is most acute.
Dupixent. Skyrizi. Tremfya. Cosentyx. Taltz. Otezla. These medications have transformed the treatment of moderate-to-severe psoriasis, atopic dermatitis, and other chronic inflammatory skin conditions. For many patients they represent the first meaningful relief they have experienced in years.
They also represent the highest prior authorization burden in dermatology.
"87% of patients require prior authorization for Humira — one of the most commonly prescribed biologics for moderate-to-severe chronic plaque psoriasis. And that is before step therapy requirements."
Step therapy is the insurer-mandated process of requiring patients to fail on cheaper, less effective medications before approving the treatment the physician already determined was appropriate. It adds weeks or months to the time between diagnosis and treatment. It causes documented patient harm. And fighting it requires the same clinical precision — and the same administrative bandwidth — as any other denial appeal.
A 2020 study found a 51% denial rate for complex dermatology requests. More than half. Denied on first submission. Each one of those denials then requires an appeal — a clinically precise, payer-specific document that argues, in the insurer's own language, why their decision was wrong and why your patient deserves the treatment you prescribed.
Most of those appeals, when filed correctly, succeed. Most never get filed at all.
The Silent Revenue Leak
Prior authorization failures cost the average dermatology clinic $83,200 per year in lost revenue.
That number deserves to sit on the page for a moment.
In winnable revenue that walked out the door because appeals weren't filed, deadlines were missed, or the administrative burden of fighting back simply exceeded the capacity of the team.
Denied prior authorizations that never get appealed. Patients who gave up after a second delay. Biologics that were prescribed but never approved. This is the silent leakage that most practices have no mechanism to track — which means they have no way to know how large it actually is.
That last part is important. Most independent dermatology practices don't know how much they're losing because they don't have the tools to measure it. The denial comes in, the staff moves to the next urgent thing, and the revenue disappears quietly.
Why Independent Practices Are Hit Hardest
Large hospital-employed dermatology departments have infrastructure that independent practices don't.
- Dedicated prior authorization coordinators whose entire job is to manage submissions, track deadlines, and fight denials — full time.
- Biologic nurses who specialize in the documentation and step therapy navigation that biologic approvals require.
- Revenue cycle managers and appeal specialists with deep payer-specific expertise built over years of institutional volume.
- Electronic submission infrastructure already integrated with every major payer portal, with established relationships and escalation paths.
The independent dermatologist is fighting this battle with a billing coordinator who also handles scheduling, insurance verification, patient calls, and a dozen other responsibilities. The insurer has an AI system processing and denying claims. Your team has a fax machine and a phone.
This asymmetry is not an accident. It is the arithmetic that makes selling your practice to a hospital system or private equity firm look rational. Let them deal with the paperwork. Let them fight the payers. You just want to practice dermatology.
That calculation is understandable. It is also one that independent dermatologists are increasingly making — and it is costing the specialty something that cannot be recovered once it is gone.
The Regulatory Tailwind — And Why It's Not Enough Alone
There is some good news on the horizon. CMS-0057-F requires payers to implement electronic prior authorization APIs, respond to urgent requests within 72 hours, and answer non-urgent requests within 7 calendar days. This rule takes full effect in 2027 and represents meaningful progress.
But faster electronic denials are not the same as fewer denials. In June 2025, more than 50 major insurers pledged to reduce prior authorization requirements and standardize electronic submissions — but these reforms are voluntary and will take years to implement, leaving practices stuck in the meantime.
The regulatory environment is improving. It is improving slowly. And in the meantime, 420 prior authorization requests arrive at your practice every year, each one demanding a response.
What Changes When AI Fights Back
MedMojo™ was built on a single conviction: independent dermatology practices deserve the same prior authorization intelligence that large health systems have built over decades — at a price point that makes the ROI immediate and measurable.
Prior Auth Intelligence™ doesn't generate generic appeal letters. It generates payer-specific submissions and appeals — built around what Aetna's medical necessity criteria actually require, what United's step therapy documentation needs to say, what Cigna's reviewers look for in a biologic authorization for atopic dermatitis.
- Every deadline is tracked automatically. No filing window closes without action. Every denial that qualifies for peer-to-peer review gets flagged before the window expires.
- Every biologic submission is optimized before it goes out. The clinical narrative is structured around the specific payer's medical necessity criteria — not a generic template.
- Every denial generates an appeal-ready response. The moment a denial comes back, MedMojo™ produces a clinically precise appeal in the language that moves that specific payer's reviewers.
The result is a practice that fights back on every denial — not just the ones that were urgent enough to survive the chaos of a busy week.
A Message to Independent Dermatologists
You didn't build an independent practice to spend your days on hold with insurance companies.
The prior authorization burden hitting dermatology right now is real, it is growing, and it is being used — whether intentionally or not — to make the administrative weight of independence feel unsustainable.
But the tools to fight back have finally arrived.
MedMojo™ is currently accepting a small number of founding pilot practices — free for three months, no contracts, no setup fees, BAA included. We work alongside your existing billing setup. Nothing gets replaced. The intelligence layer simply makes everything you're already doing more effective.
If you're an independent dermatologist in NJ, NY, CT, or PA — we'd like to talk.
Your independence is worth fighting for.